Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer

INTRODUCTION: Pembrolizumab is an established first-line option for patients with advanced non-small-cell lung cancer (NSCLC) expressing programmed death-ligand 1 ≥50%. Durable responses are seen in a subset of patients; however, many derive little clinical benefit. Biomarkers of the systemic inflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Stares, M., Ding, T.E., Stratton, C., Thomson, F., Baxter, M., Cagney, H., Cumming, K., Swan, A., Ross, F., Barrie, C., Maclennan, K., Campbell, S., Evans, T., Tufail, A., Harrow, S., Lord, H., Laird, B., MacKean, M., Phillips, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058907/
https://www.ncbi.nlm.nih.gov/pubmed/35398717
http://dx.doi.org/10.1016/j.esmoop.2022.100445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058907/
https://www.ncbi.nlm.nih.gov/pubmed/35398717
http://dx.doi.org/10.1016/j.esmoop.2022.100445

Ejemplares similares